You can’t argue against facts.
Highlighting facts and missteps is not disparaging, it’s the truth. Just one single example:
I wonder out loud if any people felt misled about the conjunctivitis dream.
2013 CEO via ASX release:“SPL7013 has the potential to be a first-in-class anti-viral agent for viral conjunctivitis (VC)” ~ a direct quote from CEO !!
”A global market of US$700m exists for effective VC treatments” ~ a direct quote from CEO !!!
”Based on feedback from potential partners and clinicians this opportunity is being advanced..” - a direct quote from CEO !!
2014:
2015:
2016:
2017:
2018:
2019:
2020:
2021:
At the 2021 Starpharma AGM during Q&A with the CEO, shareholders were made aware that SPL7013 and viral-conjunctivitis was now not a priority.
This is truly shameful. But this is quite typical of what Starpharma do, and continue to do. Hello … the Indian distribution deal which supposedly was well advanced in partnering discussions for Viraleze. Still waiting…
DYOR
You can’t argue against facts.Highlighting facts and missteps is...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.007(7.14%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 9.5¢ | 10.5¢ | 9.5¢ | $8.154K | 83.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5102 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 124847 | 3 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |